How effective is the indigenous vaccine COVAXIN against the delta variant, Bharat Biotech revealed

Mail Us For Business inquiry
- Advertisement -

corona virus (Corona Bharat Biotech has issued a statement regarding the efficacy of the indigenous vaccine Covaccine against the delta variant of the virus. Bharat Biotech has said that the results of the Phase III trial of COVAXIN among the general population showed 65.2 percent efficacy against the delta variant. Bharat Biotech said in the statement that the study also shows that the covaccine meets the WHO efficacy criteria for Kovid vaccines for the dangerous delta variant.

Rahul Gandhi targeted the government over the deaths due to Corona, demanded compensation of 4 lakhs for the relatives of the deceased

Earlier on Wednesday, a big claim was made in The Lancet Infectious Disease Journal about India’s indigenous vaccine, Covaccine. The Real World Assessment of Indian Vaccine, published on Wednesday in The Lancet Infectious Disease journal, revealed that two doses of covaccine provided only 50 per cent protection against corona during the second wave of the pandemic in India.

According to the study published in The Lancet Infectious Disease journal, the first real-world evaluation of the vaccine BBV152 (BBV152) developed by Bharat Biotech suggests that the two-dose vaccine results in 50 percent effective against symptomatic COVID infection. The study assessed 2,714 hospital workers at Delhi AIIMS from April 15 to May 15, 2021, who were symptomatic and underwent RT-PCR test for detection of COVID-19.

Cryptocurrency: What is Private Cryptocurrency? Why did the government turn its eyes on this, know everything

The Covaccine has been developed by Hyderabad-based Bharat Biotech in collaboration with the National Institute of Virology, Indian Council of Medical Research (NIV-ICMR), Pune. It is an inactivated whole virus vaccine administered in a two-dose regimen 28 days apart. In January this year, Covaccine was allowed in India for emergency use for people aged 18 years and above.

The WHO added the vaccine to its list of approved emergency use COVID-19 vaccines earlier this month. The latest study was conducted during India’s second COVID-19 surge and in healthcare workers, who were primarily offered covaccine.


- Advertisement -
Mail Us For  DMCA / Credit  Notice

Recent Articles

Stay on top - Get the daily news in your inbox

Related Stories